Physician profile
Armeen Poor
NPI 1245573369
$17,065.18
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.58 · 2020: $46.99 · 2021: $7,848 · 2022: $8,849 · 2023: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arjo INC. | $14,034.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $2,620.59 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.64 | 2020-2023 | |
| Amgen INC. | $139.47 | 2023 | Tezspire |
| Bard Access Systems, INC. | $28.83 | 2021 | |
| Teleflex LLC | $18.20 | 2023 | Arrow |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armeen Poor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.